Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Firinu

Showing results (111-120 of 120) with videos related to

Pageof 12
Sort By:
You have reached the last page of results.This site can display upto 120 results.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
American Journal of Hematology|December 18, 2023
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohortCarmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, et al.
Clinical and Translational Allergy|May 21, 2026
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA RegistryFrancesca Perego, Azzurra Cesoni Marcelli, Riccardo Senter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyAlessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, et al.
Cell|October 1, 2013
Genetic variants regulating immune cell levels in health and diseaseValeria Orrù, Maristella Steri, Gabriella Sole, et al.
The New England Journal of Medicine|April 27, 2017
Overexpression of the Cytokine BAFF and Autoimmunity RiskMaristella Steri, Valeria Orrù, M Laura Idda, et al.
Allergo Journal : Interdisziplinare Zeitschrift Fur Allergologie Und Umweltmedizin : Organ Der Deutschen Gesellschaft Fur Allergie- Und Immunitatsforschung|June 18, 2020
Ludger Klimek, Oliver Pfaar, Margitta Worm, et al.
Allergologie Select|September 11, 2020
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)<sup>A</sup>, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)<sup>B</sup>, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)<sup>C</sup>, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)<sup>D</sup>, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)<sup>E</sup>, Österreichische Gesellschaft für Pneumologie (ÖGP)<sup>F</sup> in co-operation with the German, Austrian, and Swiss ARIA groups<sup>G</sup>, and the European Academy of Allergy and Clinical Immunology (EAACI)<sup>H</sup>Ludger Klimek, Oliver Pfaar, Margitta Worm, et al.
Pageof 12

Showing results (111-120 of 120) with videos related to

Sort By:
Pageof 12
You have reached the last page of results.This site can display upto 120 results.
Allergy|February 9, 2020
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaIoana Agache, Jessica Beltran, Cezmi Akdis, et al.
Allergy|March 11, 2020
Efficacy and safety of treatment with dupilumab for severe asthma: A systematic review of the EAACI guidelines-Recommendations on the use of biologicals in severe asthmaIoana Agache, Yang Song, Claudio Rocha, et al.
British Journal of Haematology|November 13, 2024
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndromeCarmelo Gurnari, Elisa Galossi, Eleonora Lumia, et al.
American Journal of Hematology|December 18, 2023
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohortCarmelo Gurnari, Maria Rosaria Pascale, Antonio Vitale, et al.
Clinical and Translational Allergy|May 21, 2026
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA RegistryFrancesca Perego, Azzurra Cesoni Marcelli, Riccardo Senter, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis: A European Multicenter Observational StudyAlessandra Bettiol, Maria Letizia Urban, Lorenzo Dagna, et al.
Cell|October 1, 2013
Genetic variants regulating immune cell levels in health and diseaseValeria Orrù, Maristella Steri, Gabriella Sole, et al.
The New England Journal of Medicine|April 27, 2017
Overexpression of the Cytokine BAFF and Autoimmunity RiskMaristella Steri, Valeria Orrù, M Laura Idda, et al.
Allergo Journal : Interdisziplinare Zeitschrift Fur Allergologie Und Umweltmedizin : Organ Der Deutschen Gesellschaft Fur Allergie- Und Immunitatsforschung|June 18, 2020
Ludger Klimek, Oliver Pfaar, Margitta Worm, et al.
Allergologie Select|September 11, 2020
Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemic: Position paper of Ärzteverband Deutscher Allergologen (AeDA)<sup>A</sup>, Deutsche Gesellschaft für Allergologie und Klinische Immunologie (DGAKI)<sup>B</sup>, Gesellschaft für Pädiatrische Allergologie und Umweltmedizin (GPA)<sup>C</sup>, Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI)<sup>D</sup>, Luxemburgische Gesellschaft für Allergologie und Immunologie (LGAI)<sup>E</sup>, Österreichische Gesellschaft für Pneumologie (ÖGP)<sup>F</sup> in co-operation with the German, Austrian, and Swiss ARIA groups<sup>G</sup>, and the European Academy of Allergy and Clinical Immunology (EAACI)<sup>H</sup>Ludger Klimek, Oliver Pfaar, Margitta Worm, et al.
Pageof 12